Release of doxorubicin hydrochloride from acrylic bone cement
| Autor: | Kazuhiro Inukai, Hiroko Saito, Mitsuru Takahashi, Nami Tanida |
|---|---|
| Rok vydání: | 1997 |
| Předmět: | |
| Zdroj: | Drug Delivery System. 12:121-125 |
| ISSN: | 1881-2732 0913-5006 |
| DOI: | 10.2745/dds.12.121 |
| Popis: | Doxorubicin hydrochloride (ADR) is an antineoplastic substance which has a wide therapeutic range against human solid tumors, lymphomas, and acute leukemias. However ADR has the risk of cardiotoxicity and marrow dipression as side effects. Acrylic bone cement conteining ADR (ADR-bone cement) has been used for filling the bony defect and for controlling local recurrences after excision of malignant tumors in our hospital. We investigate the release of ADR from ADR-bone cement in vitro and in vivo elution studies for assessing usefullness of ADR-bone cement as drug delivery system. The release of ADR from ADR-bone cement has two phases. First phase of the release was supposed to occur a very high discharge from the external-surface of the cement, and secondary from the pores of the cement. In vitro elution studies, the release of ADR from ADR-bone cement was eluted slowly during over 12 weeks. 50 percentage of the total released ADR was eluted within 1 hour, 90 percentage within 1 week. During 12 weeks 0.6-1.6 percentage of the total ADR implanted was released. The concentration of ADR in drain fluid of the patient implanted ADR-bone cement is higher than the serum concentration of ADR of the patient dosed 30 mg ADR intravenously. However, the patient implanted ADR-bone cement has no symptoms like general side effects, necrosis, dead spase fluid and infection by local high concentration of ADR. Our studies show the possibility of long and local administration of ADR by ADR-bone cement. This topical administration decrease general side effects and is a useful drug delivery system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|